Novo Nordisk
-
healthUK Approves First Daily Oral GLP-1 Semaglutide for Obesity Treatment
Novo Nordisk secures UK approval for daily oral semaglutide, offering a non-injectable alternative for obesity management with significant weight loss results in clinical trials.
-
healthBoehringer's Obesity Drug Shows Promising Weight Loss, Flagging Tolerability Concerns
Boehringer Ingelheim releases detailed phase 3 obesity drug data: 16.6% weight loss, significant liver fat reduction, but tolerability issues spark investor sell-off.
-
healthSemaglutide Boosts Quality of Life in Diabetes and Kidney Disease Patients
New FLOW trial data shows semaglutide improves daily functioning and well-being in adults with type 2 diabetes and chronic kidney disease.
-
healthCanada Approves Generic Ozempic; US Waits Until 2032
Canada becomes first G7 nation to approve generic semaglutide. US patients face patent barriers until 2032, sparking cross-border interest.
-
healthGLP-1 Drugs Like Ozempic Show Broad Cancer Protection Promise
Multiple studies at ASCO 2024 show GLP-1 drugs reduce cancer risk and improve outcomes across tumor types, with potential benefits tied to inflammation reduction and weight loss.
-
healthFrance Becomes First EU Country to Reimburse Weight-Loss Drugs
France will start covering costs of Wegovy and Mounjaro from June 15, a historic move making it the first EU nation to offer permanent reimbursement for GLP-1 weight-loss medications.
-
healthNovo Nordisk Cuts Ozempic Price in Canada to Compete with Generics
Novo Nordisk reduces Ozempic cost for uninsured Canadians as generic semaglutide enters the market, slashing prices by roughly a third.
-
healthPeptide Craze Surges Beyond GLP-1s as FDA Faces Pressure to Ease Access
The peptide market is exploding amid regulatory tensions, with the FDA set to consider loosening restrictions on several peptides this summer.